Combination with intravenous iron supplementation or doubling erythropoietin dose for patients with chemotherapy-induced anaemia inadequately responsive to initial erythropoietin treatment alone: study protocol for a randomised controlled trial

Lin Chen, Hong Jiang, Wei Gao, Ye Tu, Ying Zhou, Xi Li, Zhe Zhu, Qixin Jiang, Haifeng Zhan, Jiangming Yu, Chuangang Fu, Yong Gao, Lin Chen, Hong Jiang, Wei Gao, Ye Tu, Ying Zhou, Xi Li, Zhe Zhu, Qixin Jiang, Haifeng Zhan, Jiangming Yu, Chuangang Fu, Yong Gao

Abstract

Introduction: Erythropoietin (EPO) is a commonly used option in the treatment of chemotherapy-induced anaemia (CIA). However, ∼30-50% of patients fail to achieve an adequate response after initial treatment. Prior studies have demonstrated that intravenous iron might synergistically improve therapeutic response to EPO treatment in this patient population.

Methods and analysis: We will perform this multicentre, randomised, open-label, parallel-group, active controlled non-inferiority study to compare the two combination therapies of EPO plus intravenous iron regimen versus doubling the dose of EPO in patients with CIA who have an inadequate response to initial EPO treatment at a routine dose. A total of 603 patients with an increase in haemoglobin (Hb) <1 g/dL will be enrolled and randomised to one of the three study treatment groups at a 1:1:1 ratio Group 1: EPO treatment at the original dose plus intravenous iron dextran 200 mg every 3 weeks (Q3W) for 15 weeks; Group 2: EPO treatment at the original dose plus intravenous iron dextran 100 mg, twice a week for 5 weeks; Group 3: the control group, doubling the EPO dose without preplanned iron supplementation. The primary outcome measure to compare is the Hb response rate at week 15 and the secondary end points involve therapeutic blood transfusions. Time-to-progression, adverse events and quality of life will also be evaluated.

Ethics and dissemination: All participants will provide informed consent; the study protocol has been approved by the independent ethics committee of Shanghai East Hospital. This study would clearly demonstrate the potential benefit of combining epoetin treatment with intravenous iron supplementation. Findings will be shared with participating hospitals, policymakers and the academic community to promote the clinical management of CIA in China.

Trial registration number: NCT02731378.

Keywords: chemotherapy-induced anaemia; erythropoietin; inadequately responsive; iron supplementation; randomized controlled trial.

Conflict of interest statement

Conflicts of Interest: None declared.

Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.

Figures

Figure 1
Figure 1
Study flow chart. CIA, chemotherapy-induced anaemia; ECOG, Eastern Cooperative Oncology Group; EPO, erythropoietin; FACT-An, Functional Assessment of Cancer Therapy-Anaemia; Hb, haemoglobin; IU, International Unit; KPS, Karnofsky Performance Status Scale; LASA, Linear Analogue Self-assessment; Q3W, Every 3 weeks.

References

    1. Groopman JE, Itri LM. Chemotherapy-induced anaemia in adults: incidence and treatment. J Natl Cancer Inst 1999;91:1616–34. 10.1093/jnci/91.19.1616
    1. Littlewood TJ, Bajetta E, Nortier JW et al. . Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001;19:2865–74.
    1. Ludwig H, Van Belle S, Barrett-Lee P et al. . The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer 2004;40:2293–306. 10.1016/j.ejca.2004.06.019
    1. Gabrilove JL, Cleeland CS, Livingston RB et al. . Clinical evaluation of once-weekly dosing of epoetin alfa in chemotherapy patients: improvements in hemoglobin and quality of life are similar to three-times-weekly dosing. J Clin Oncol 2001;19:2875–82.
    1. Osterborg A, Brandberg Y, Molostova V et al. . Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin beta, in hematologic malignancies. J Clin Oncol 2002;20:2486–94. 10.1200/JCO.2002.08.131
    1. Boogaerts M, Coiffier B, Kainz C; Epoetin Beta QOL Working Group. Impact of epoetin beta on quality of life in patients with malignant disease. Br J Cancer 2003;88:988–95. 10.1038/sj.bjc.6600801
    1. Mäenpää J, Puistola U, Riska H et al. . Impact of epoetin-beta on anaemia and health-related quality of life in cancer patients: a prospective observational study using the generic 15D instrument. Anticancer Res 2014;34:2325–9.
    1. Hedley BD, Chu JE, Ormond DG et al. . Recombinant human erythropoietin in combination with chemotherapy increases breast cancer metastasis in preclinical mouse models. Clin Cancer Res 2011;17:6151–62. 10.1158/1078-0432.CCR-10-3298
    1. Hedley BD, Allan AL, Xenocostas A. The role of erythropoietin and erythropoiesis-stimulating agents in tumor progression. Clin Cancer Res 2011;17:6373–80. 10.1158/1078-0432.CCR-10-2577
    1. Todaro M, Turdo A, Bartucci M et al. . Erythropoietin activates cell survival pathways in breast cancer stem-like cells to protect them from chemotherapy. Cancer Res 2013;73:6393–400. 10.1158/0008-5472.CAN-13-0248
    1. Zhou B, Damrauer JS, Bailey ST et al. . Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. J Clin Invest 2014;124:553–63. 10.1172/JCI69804
    1. Liang K, Qiu S, Lu Y et al. . Autocrine/paracrine erythropoietin regulates migration and invasion potential and the stemness of human breast cancer cells. Cancer Biol Ther 2014;15:89–98. 10.4161/cbt.26717
    1. Aapro MS, Link H. September 2007 update on EORTC guidelines and anaemia management with erythropoiesis-stimulating agents. Oncologist 2008;13(Suppl 3):33–6. 10.1634/theoncologist.13-S3-33
    1. Bokemeyer C, Aapro MS, Courdi A et al. . EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update. Eur J Cancer 2007;43:258–70. 10.1016/j.ejca.2006.10.014
    1. Rodgers GM 3rd, Becker PS, Blinder M et al. . Cancer- and chemotherapy-induced anaemia. J Natl Compr Canc Netw 2012;10:628–53.
    1. Rizzo JD, Brouwers M, Hurley P et al. . American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood 2010;116:4045–59. 10.1182/blood-2010-08-300541
    1. Experts Committee on Cancer -Related Anaemia; Chinese Society of Clinical Oncology (CSCO). Clinical practice guidelines on cancer-related anaemia (2012–2013 Edition). Chin Clin Oncol 2012;1:18 10.3978/j.issn.2304-3865.2012.10.01
    1. Means RT Jr, Krantz SB. Progress in understanding the pathogenesis of the anaemia of chronic disease. Blood 1992;80:1639–47.
    1. Demetri GD, Kris M, Wade J et al. . Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. Procrit Study Group. J Clin Oncol 1998;16:3412–25.
    1. Glaspy J, Bukowski R, Steinberg D et al. . Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol 1997;15:1218–34.
    1. Glaspy J, Cavill I. Role of iron in optimizing responses of anemic cancer patients to erythropoietin. Oncology (Williston Park, NY) 1999;13:461–73. discussion 477–8, 483–8.
    1. Glaspy J, Beguin Y. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon). Oncology 2005;69:8–16. 10.1159/000088283
    1. Cavill I, Auerbach M, Bailie GR et al. . Iron and the anaemia of chronic disease: a review and strategic recommendations. Curr Med Res Opin 2006;22:731–7. 10.1185/030079906X100096
    1. Pedrazzoli P, Rosti G, Secondino S et al. . Iron supplementation and erythropoiesis-stimulatory agents in the treatment of cancer anemia. Cancer 2009;115:1169–73. 10.1002/cncr.24115
    1. Auerbach M, Ballard H, Trout JR et al. . Intravenous iron optimizes the response to recombinant human erythropoietin in cancer patients with chemotherapy- related anemia: a multicenter, open-label, randomized trial. J Clin Oncol 2004;22:1301–7. 10.1200/JCO.2004.08.119
    1. Pedrazzoli P, Farris A, Del Prete S et al. . Randomized trial of intravenous iron supplementation in patients with chemotherapy-related anemia without iron deficiency treated with darbepoetin alpha. J Clin Oncol 2008;26:1619–25. 10.1200/JCO.2007.12.2051
    1. Agarwal R, Kusek JW, Pappas MK. A randomized trial of intravenous and oral iron in chronic kidney disease. Kidney Int 2015;88:905–14. 10.1038/ki.2015.163
    1. Charytan DM, Pai AB, Chan CT et al. . Considerations and challenges in defining optimal iron utilization in hemodialysis. J Am SocNephrol 2015;26:1238–47. 10.1681/ASN.2014090922
    1. Zitt E, Sturm G, Kronenberg F et al. . Iron supplementation and mortality in incident dialysis patients: an observational study. PLoS ONE 2014;9:e114144 10.1371/journal.pone.0114144
    1. Kshirsagar AV, Freburger JK, Ellis AR et al. . Intravenous iron supplementation practices and short-term risk of cardiovascular events in hemodialysis patients. PLoS ONE 2013;8:e78930 10.1371/journal.pone.0078930
    1. Petrelli F, Borgonovo K, Cabiddu M et al. . Addition of iron to erythropoiesis-stimulating agents in cancer patients: a meta-analysis of randomized trials. J Cancer Res Clin Oncol 2012;138:179–87. 10.1007/s00432-011-1072-3
    1. Steensma DP, Sloan JA, Dakhil SR et al. . Phase III, randomized study of the effects of parenteral iron, oral iron, or no iron supplementation on the erythropoietic response to darbepoetin alfa for patients with chemotherapy-associated anemia. J Clin Oncol 2011;29:97–105. 10.1200/JCO.2010.30.3644
    1. Gafter-Gvili A, Rozen-Zvi B, Vidal L et al. . Intravenous iron supplementation for the treatment of chemotherapy-induced anaemia—systematic review and meta-analysis of randomised controlled trials. Acta Oncol 2013;52:18–29. 10.3109/0284186X.2012.702921
    1. Mhaskar R, Wao H, Miladinovic B et al. . The role of iron in the management of chemotherapy-induced anemia in cancer patients receiving erythropoiesis-stimulating agents. Cochrane Database Syst Rev 2016;2:CD009624 10.1002/14651858.CD009624.pub2
    1. Therasse P, Arbuck SG, Eisenhauer EA et al. . New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205–16.
    1. Bastit L, Vandebroek A, Altintas S et al. . Randomized, multicenter, controlled trial comparing the efficacy and safety of darbepoetin alfa administered every 3 weeks with or without intravenous iron in patients with chemotherapy-induced anemia. J Clin Oncol 2008;26:1611–18. 10.1200/JCO.2006.10.4620
    1. Luporsi E, Mahi L, Morre C et al. . Evaluation of cost savings with ferric carboxymaltose in anaemia treatment through its impact on erythropoiesis-stimulating agents and blood transfusion: French healthcare payer perspective. J Med Econ 2012;15:225–32. 10.3111/13696998.2011.639823
    1. Pashos CL, Larholt K, Fraser KA et al. . Outcomes of erythropoiesis-stimulating agents in cancer patients with chemotherapy-induced anemia. Support Care Cancer 2012;20:159–65. 10.1007/s00520-010-1083-7
    1. National Cancer Institute (USA). Common Terminology Criteria for Adverse Events (CTCAE) version 4.0. 2010. (last accessed 10 Dec 2015).
    1. Fujisaka Y, Sugiyama T, Saito H et al. . Randomised, phase III trial of epoetin-β to treat chemotherapy-induced anaemia according to the EU regulation. Br J Cancer 2011;105:1267–72. 10.1038/bjc.2011.395
    1. Aickin M, Gensler H. Adjusting for multiple testing when reporting research results: the Bonferroni vs Holm methods. Am J Public Health 1996;86:726–8. 10.2105/AJPH.86.5.726
    1. Hedenus M, Näsman P, Liwing J. Economic evaluation in Sweden of epoetin beta with intravenous iron supplementation in anaemic patients with lymphoproliferative malignancies not receiving chemotherapy. J Clin Pharm Ther 2008;33:365–74. 10.1111/j.1365-2710.2008.00924.x
    1. Hedenus M, Adriansson M, San Miguel J et al. . Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study. Br J Haematol 2003;122:394–403.
    1. Amgen Announces Interim Results of Aranesp? “PREPARE” Study in Breast Cancer Patients. (last accessed 10 Dec 2015).
    1. Smith RE Jr, Aapro MS, Ludwig H et al. . Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebocontrolled study. J Clin Oncol 2008;26:1040–50. 10.1200/JCO.2007.14.2885
    1. Henke M, Laszig R, Rübe C et al. . Erythropoietin to treat head and neck cancer patients with anaemia undergoing radiotherapy: randomised, double-blind, placebo-controlled trial. Lancet 2003;362:1255–60. 10.1016/S0140-6736(03)14567-9
    1. Leyland-Jones B, Semiglazov V, Pawlicki M et al. . Maintaining normal hemoglobin levels with epoetin alfa in mainly nonanemic patients with metastatic breast cancer receiving first-line chemotherapy: a survival study. J Clin Oncol 2005;23:5960–72.
    1. Thomas G, Ali S, Hoebers FJ et al. . Phase III trial to evaluate the efficacy of maintaining hemoglobin levels above 12.0 g/dL with erythropoietin vs above 10.0 g/dL without erythropoietin in anemic patients receiving concurrent radiation and cisplatin for cervical cancer. Gynecol Oncol 2008;108:317–25. 10.1016/j.ygyno.2007.10.011
    1. Wright JR, Ung YC, Julian JA et al. . Randomized, double-blind, placebocontrolled trial of erythropoietin in non-small-cell lung cancer with disease-related anemia. J Clin Oncol 2007;25:1027–32.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel